{"nctId":"NCT00127530","briefTitle":"Study of Oral Fampridine-SR in Multiple Sclerosis","startDateStruct":{"date":"2005-05"},"conditions":["Multiple Sclerosis"],"count":300,"armGroups":[{"label":"Placebo- sugar pill","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Fampridine-SR","type":"EXPERIMENTAL","interventionNames":["Drug: Fampridine-SR"]}],"interventions":[{"name":"Fampridine-SR","otherNames":["Sustained release 4-aminopyridine, 4-AP"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a confirmed diagnosis of multiple sclerosis\n* Are able to walk with or without an assistive device\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding or females of childbearing potential not using adequate birth control\n* Participating in other investigational drug trials\n* A medical history or clinical findings that preclude entry into the study\n* A medication history that precludes entry into the study\n* Previously treated with 4-aminopyridine (4-AP)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk)","description":"Patients who showed a faster walking speed for at least three of the four on-drug visits during the double-blind treatment period as compared to the maximum speed for any of the five off-drug visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Lower Extremity Manual Muscle Test; Ashworth Score for Spasticity","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":72},"commonTop":["fall","Urinary Tract Infection","dizziness","insomnia","Upper Respiratory Tract infection"]}}}